GlassScriptPhysician profile
Tamar Lipof
NPI 1447447123
$846.55
in general payments reported to CMS, 2019-2025
10 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $70.00 · 2022: $136 · 2023: $163 · 2024: $97.69 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $223.81 | 2022-2025 | Integra, Surgimend, Omnigraft |
| Mimedx Group, INC. | $189.94 | 2025 | |
| Activ Surgical, INC. | $121.59 | 2023 | Activsight |
| Boston Scientific Corporation | $113.07 | 2023-2024 | X-Tack Endoscopic Helix Tacking System, Exalt Model D |
| Intuitive Surgical, INC. | $70.00 | 2020 | |
| Lsi Solutions INC | $34.99 | 2019 | |
| Zimmer Biomet Holdings, INC. | $27.30 | 2019 | |
| Ethicon US, LLC | $25.54 | 2024 | Echelon; Endopath |
| Covidien LP | $21.87 | 2019 | |
| Braintree Laboratories, INC. | $18.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamar Lipof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.